Last reviewed · How we verify
Intermediate dose enoxaparin
Intermediate dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Intermediate dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboprophylaxis in medical and surgical patients, Treatment of acute deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.
At a glance
| Generic name | Intermediate dose enoxaparin |
|---|---|
| Also known as | enoxaparin, Clexane |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Coagulation factors Xa and IIa (via antithrombin III) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin is derived from unfractionated heparin and works by potentiating antithrombin III, which inactivates coagulation factors Xa and thrombin (IIa). The intermediate dose formulation provides a balance between anticoagulant efficacy and bleeding risk, making it suitable for thromboprophylaxis and treatment of thromboembolic conditions. It is administered subcutaneously and has predictable pharmacokinetics.
Approved indications
- Thromboprophylaxis in medical and surgical patients
- Treatment of acute deep vein thrombosis and pulmonary embolism
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
Key clinical trials
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration. (NA)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk (PHASE4)
- Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (PHASE4)
- Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients (PHASE2)
- Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial (PHASE2, PHASE3)
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |